Home  /  Resource Library  /  Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Results of a phase II study investigating the combination of Dabrafenib and Trametinib for treating relapsed BRAF V600E Hairy Cell Leukemia.